Becton, Dickinson (BDX +2.40%) is emerging as a compelling investment in the healthcare sector, which has seen per capita spending soar from $353 in 1970 to an expected $15,474 in 2024. Unlike pharmaceutical companies facing price pressures and potential profit declines, BDX generates steady revenue from essential medical products like syringes and catheters, ensuring consistent demand. The company’s dividend yield of 2.7% has been growing annually for over 50 years, with a recent increase from $0.83 to $1.05 per share anticipated by 2026.
BDX’s stock is currently trading at a forward price-to-earnings (P/E) ratio of 12, significantly below its five-year average of 17, suggesting it is undervalued and provides a margin of safety for investors. The company’s recent $250 million share buyback indicates management’s confidence in its value and commitment to returning capital to shareholders.
For market professionals, Becton, Dickinson represents a solid choice for those seeking stability and income in a volatile healthcare landscape.
Source: fool.com